Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2006-001770-25
    Sponsor's Protocol Code Number:IDT.ES.LEV.22006
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2006-06-29
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2006-001770-25
    A.3Full title of the trial
    Ensayo clínico unicéntrico, cruzado, aleatorizado, doble ciego, controlado con placebo, para evaluar la calidad de la vida sexual en pacientes alcohólicos afectados de DE tras un tratamiento con vardenafilo / Unicenter double-blind, cross-over, randomised, placebo controlled clinical trial to evaluate the sexual quality of life in alcoholic subjects with E.D. after a treatment with vardenafil
    A.3.2Name or abbreviated title of the trial where available
    DESEA
    A.4.1Sponsor's protocol code numberIDT.ES.LEV.22006
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDr Antoni Gual, Hospital Clínic de Barcelona, Unitat d'Alcohologia de la Generalitat de Catalunya
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Levitra 5 MG
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVardenafil (hidrocloride)
    D.3.4Pharmaceutical form Buccal tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVARDENAFILO HIDROCLORURO
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Information not present in EudraCT
    D.3.11.8Extractive medicinal product Information not present in EudraCT
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Levitra 10 MG
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVardenafil (hidrocloride)
    D.3.4Pharmaceutical form Buccal tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVARDENAFILO HIDROCLORURO
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Information not present in EudraCT
    D.3.11.8Extractive medicinal product Information not present in EudraCT
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Levitra 20 MG
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVardenafil (hidrocloride)
    D.3.4Pharmaceutical form Buccal tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVARDENAFILO HIDROCLORURO
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Information not present in EudraCT
    D.3.11.8Extractive medicinal product Information not present in EudraCT
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboBuccal tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Disfunción Eréctil / Erectile Dysfunction
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Comparar la eficacia de vardenafilo versus placebo en la mejora de la puntuación del dominio de calidad de vida sexual del cuestionario SLQQ en pacientes alcohólicos con DE que ya estén desintoxicados.
    E.2.2Secondary objectives of the trial
    Comparar la eficacia de vardenafilo versus placebo en la mejora de la puntuación del dominio de calidad de vida sexual del cuestionario SLQQ en el paciente y su pareja.

    Comparar la eficacia de vardenafilo versus placebo en términos de mejora:
    • de la puntuación del dominio de la satisfacción con el tratamiento (cuestionario SLQQ) del paciente y su pareja
    • de la FE del cuestionario IIEF (The International Index of Erectile Function)
    • de las puntuaciones del diario de paciente
    • global de las erecciones (cuestionario GAQ)
    E.2.3Trial contains a sub-study Information not present in EudraCT
    E.3Principal inclusion criteria
    1. Hombres con disfunción eréctil según la definición del NIH Consensus Conference 7-9 Diciembre 1992 (incapacidad para lograr o mantener una erección del pene el tiempo suficiente para una relación sexual satisfactoria).

    2. Hombres de edad comprendida entre los 18 y 64 años que son atendidos en su solicitud de deseo de dejar de beber.

    3. Pacientes que ya estén desintoxicados.

    4. Pacientes que durante el periodo basal sin tratamiento (primeras 2-4 semanas) no hayan manifestado efectos secundarios que puedan confundirse con los provocados por vardenafilo (cefalea, rubefacción, dispepsia, náusea, mareos, rinitis y trastornos visuales).

    5. Relación heterosexual estable.

    6. El paciente debe realizar al menos cuatro intentos de relación sexual en cuatro días diferentes durante el periodo basal sin tratamiento (según la respuesta a la siguiente pregunta del diario de paciente: “¿Intentó realizar el acto sexual?”).

    7. Al menos el 50% de los intentos de relación sexual durante el período basal sin tratamiento deben haber sido infructuosos según las siguientes preguntas del diario de paciente (se debe responder “no” al menos a una de ellas: “¿Fue capaz de conseguir al menos un poco de erección (creció su pene)?” (SEP 1); “¿Fue capaz de meter su pene en la vagina de su pareja?” (SEP 2); “¿Su erección duró lo suficiente para que usted realizara el acto sexual con éxito?” (SEP 3).

    8. Obtención del Consentimiento informado por escrito.
    E.4Principal exclusion criteria
    A) Patologías médicas actuales o previas

    1. Cualquier proceso médico o psiquiátrico inestable o abuso de sustancias que, en opinión del investigador, pudiera afectar a la capacidad del paciente para completar el estudio o impida su participación en el mismo.

    2. Presencia de anormalidades peneanas anatómicas (p. ej. fibrosis peneana o enfermedad de Peyronie) que pudieran deteriorar de forma significativa la función eréctil a criterio del investigador.

    3. Deseo sexual hipoactivo primario.

    4. Antecedente de prostatectomía quirúrgica (excluyendo Resección Trans-uretro Prostática).

    5. Historia de lesión medular.

    6. Retinitis pigmentaria.

    7. Angina de pecho inestable.

    8. Antecedentes de infarto de miocardio, accidente cerebral vascular agudo o arritmia con peligro para la vida en los seis meses previos.

    9. Taquiarritmia auricular (p. ej. debida a fibrilación o flutter auricular) con una frecuencia cardíaca superior a 100 latidos por minuto en el momento de la selección.

    10. Insuficiencia hepática moderada o severa (Child-Pugh B ó C).

    11. Enfermedad hematológica crónica clínicamente significativa como anemia falciforme y leucemia que puede conllevar a priapismo.

    12. Trastorno hemorrágico.

    13. Enfermedad ulcerosa péptica activa.

    14. Hipotensión (presión arterial sistólica en reposo < 90 mmHg) o hipertensión de reposo (presión arterial sistólica en reposo > 170 mmHg o presión arterial diastólica en reposo > 110 mmHg).

    15. Antecedente de neoplasia durante los últimos cinco años (excepto carcinoma de células escamosas o basocelular de la piel).

    16. Insuficiencia cardíaca Clase III y IV (NYHA).

    17. Insuficiencia renal grave (aclaramiento de creatinina <30 ml/min)

    18. Historia de test positivo para el antígeno de superficie de la hepatitis B (Antígeno HBs) o hepatitis C.

    19. Hipotensión ortostática sintomática en los 6 meses previos a visita 1.

    20. Pacientes con un episodio previo de neuropatía óptica isquémica no arterítica (NOIA-NA).

    B) Medicación concomitante

    1. Pacientes que están tomando nitratos o liberadores del óxido nítrico.

    2. Pacientes que están tomando andrógenos (p.ej. testosterona) o antiandrógenos.

    3. Pacientes que están tomando los siguientes inhibidores del citocromo P450 3A4: eritromicina, inhibidores potentes de la proteasa del VIH (ritonavir, indinavir) o los antimicóticos itraconazol y ketoconazol (se permiten en formulación tópica).

    4. Pacientes que han recibido cualquier fármaco en investigación (incluido placebo) en los 30 días anteriores a la visita 1.

    5. Utilización de cualquier tratamiento para la DE en los 7 días anteriores a la visita de selección o durante el estudio, incluyendo medicación oral, sistemas de vacío, dispositivos constrictores, inyecciones o supositorios uretrales.

    6. Pacientes en tratamiento con alfabloqueantes

    C) Valores anormales de laboratorio

    1. Pacientes con un valor de testosterona sérica total > 25% inferior al límite inferior del rango de normalidad (de acuerdo a los valores de normalidad especificados por el laboratorio centralizado).

    2. Pacientes con una creatinina sérica > 2.5 mg/dL.

    3. Elevación de AST y ALT > 3 veces el límite superior de la normalidad.

    4. Pacientes diabéticos con Hemoglobina A1c>12%.


    D) Otros criterios de exclusión

    1. Pacientes que no desean dejar de utilizar sistemas de vacío, inyecciones intracavernosas, Viagra®, Cialis® u otro tratamiento de la DE durante el estudio.

    2. Falta de disposición del paciente o de su pareja para realizar 4 intentos de relación sexual en 4 días distintos durante el período basal sin tratamiento.

    3. Hipersensibilidad conocida a cualquier componente del medicamento en investigación, incluyendo hipersensibilidad a la lactosa.

    4. Pacientes analfabetos o incapaces de comprender el lenguaje en que se presentan los cuestionarios o que no estén dispuestos a cumplimentar el diario del paciente.

    5. Historia dentro de los últimos 6 meses de cefaleas migrañosas graves ocurriendo una vez al mes o más frecuentemente.

    6. Pacientes que no puedan dejar de tomar zumo de pomelo o productos que contengan zumo de pomelo con la medicación del estudio.


    E.5 End points
    E.5.1Primary end point(s)
    Comparación de la puntuación de la dimensión de Calidad de Vida Sexual (cuestionario SLQQ) en el periodo en tratamiento con vardenafilo vs el periodo en tratamiento con placebo de vardenafilo, en el paciente.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Information not present in EudraCT
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Calidad de Vida Sexual y satisfacción con el tratamiento
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee Information not present in EudraCT
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Information not present in EudraCT
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Information not present in EudraCT
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Information not present in EudraCT
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 40
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2006-08-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2006-07-26
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 21:06:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA